InMed Pharmaceuticals (INM) Short-term Investments (2020 - 2026)

InMed Pharmaceuticals' Short-term Investments history runs 7 years deep, the most recent figure standing at $41625.0 for Q1 2026.

• On a quarterly basis, Short-term Investments rose 2.57% year-over-year to $41625.0 in Q1 2026; TTM through Mar 2026 was $41625.0, a 2.57% increase from a year earlier, with the FY2025 full-year figure at $43384.0, up 0.74% from the prior year.
• Short-term Investments fell to $41625.0 in Q1 2026 per INM's latest filing, from $42675.0 in the prior quarter.
• Across five years, Short-term Investments topped out at $46098.0 in Q1 2022 and bottomed at $40582.0 in Q1 2025.
• The 5-year median for Short-term Investments is $43055.0 (2023), against an average of $43072.1.
• Across the five-year window, Short-term Investments decreased 8.27% in 2024 and grew 4.63% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $43053.0 in 2022, then grew by 3.27% to $44462.0 in 2023, then dropped by 8.27% to $40787.0 in 2024, then climbed by 4.63% to $42675.0 in 2025, then fell by 2.46% to $41625.0 in 2026.
• Per Business Quant, the three latest INM Short-term Investments figures stand at $41625.0 (Q1 2026), $42675.0 (Q4 2025), and $42859.0 (Q3 2025).